STAT6 Inhibitor Program

About Enanta Pharmaceuticals

Enanta Pharmaceuticals is a clinical-stage biotech focused on discovering and developing oral small-molecule drugs for virology and immunology. The company's foundational achievement was its collaboration with AbbVie that yielded two HCV protease inhibitors, glecaprevir and paritaprevir, which are components of blockbuster combination therapies. Its current strategy pivots on advancing its lead RSV N-protein inhibitor, zelicapavir (EDP-938), and building an immunology pipeline targeting KIT, STAT6, and MRGPRX2 for diseases like chronic spontaneous urticaria. Enanta aims to replicate its HCV success by applying rigorous structure-based drug design to areas of significant unmet medical need.

Therapeutic Areas